Navigation Links
InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
Date:2/3/2009

ents were randomized 1:1 to receive a total daily dose of 2403 mg pirfenidone, or placebo. CAPACITY 2 enrolled a total of 435 patients, and patients were randomized 2:2:1 to receive a total daily dose of 2403 mg pirfenidone, or placebo, or a total daily dose of 1197 mg pirfenidone, respectively, administered in three divided doses. The lower dose of pirfenidone in CAPACITY 2 provided safety and tolerability data. The pre-specified statistical analysis plan did not call for this low-dose group to be used in any analyses of efficacy. The pooled analyses of the primary and secondary efficacy outcome measures were based on a combined analysis of the 2403 mg group compared with the placebo group across both studies and were considered exploratory.

Enrollment of both trials was completed in less than 13 months following randomization of the first patient into the program in late April 2006. Ninety-seven percent (97%) of all patients in the two CAPACITY studies who were living and had not received a lung transplant, completed their Week 72 study visit.

Each trial in CAPACITY was designed to have greater than 95% statistical power to detect a 50% reduction in the rate of FVC progression compared to placebo after 72 weeks of treatment and greater than 85% statistical power to detect a 40% reduction after the same period, when compared to placebo. The pre-specified secondary endpoints of CAPACITY were:

        1.  Time to worsening of IPF, defined as time to acute IPF
            exacerbation, IPF-related death, lung transplant or respiratory
            hospitalization, whichever comes first
        2.  Progression-free survival defined as time to the first occurrence
            of either of the following (as compared to the patient's
            baseline):
              --  10% absolute decline in percent predicted FVC, or
              --  15% absolute decline in percent predicted Hb-corrected
        
'/>"/>
SOURCE InterMune
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. InterMune to Present at J.P. Morgan Healthcare Conference
2. InterMune to Present at Deutsche Bank Biotech Boston Confab
3. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
4. InterMune to Release Third Quarter 2008 Financial Results on November 6
5. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
6. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
7. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
8. InterMune to Present at Canaccord Adams Conference
9. InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
10. InterMune to Present at BMO Healthcare Conference
11. InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... , June 29, 2015 According ... (DNA, RNA, XNA), by Application (Diagnostics, Therapeutics, R&D), by Technology ... & Pharmaceutical Companies, CRO) - Global Forecast to 2020", published ... $244.93 Million by 2020 from $107.56 Million in 2015, at ... T ables and 67 F igures ...
(Date:6/29/2015)... --  For the seventh year running, Across Health conducted a ... maturity called the Multichannel Maturometer . The research ... fast enough. While it,s true that technology is indeed ... customers are increasingly "digital natives", pharma still lags behind ... Logo ...
(Date:6/26/2015)... , June 26, 2015   Aratana ... a pet therapeutics company focused on the ... products for companion animals, today announced positive ... of capromorelin (AT-002), the company,s innovative therapeutic ... a small molecule that mimics ghrelin, the ...
(Date:6/26/2015)... Va. , June 26, 2015  A San ... two products made with synthetic rhino horn: beer in ... Vietnam . In response to the ... the manufacture, marketing and sale of synthetic rhino horn.  ... and Save the Rhino International (SRI) ...
Breaking Biology Technology:Aptamers Market Worth $244.93 Million by 2020 2Aptamers Market Worth $244.93 Million by 2020 3Aptamers Market Worth $244.93 Million by 2020 4Results from Digital Maturity Study Show Pharma Lagging 2Results from Digital Maturity Study Show Pharma Lagging 3Results from Digital Maturity Study Show Pharma Lagging 4Aratana Therapeutics Announces Positive Pivotal Results for AT-002 2Aratana Therapeutics Announces Positive Pivotal Results for AT-002 3Aratana Therapeutics Announces Positive Pivotal Results for AT-002 4Aratana Therapeutics Announces Positive Pivotal Results for AT-002 5Rhino Experts Oppose Synthetic Rhino Horn as Solution to Poaching Crisis 2
... FOLD ) today announced that John Crowley, President and ... Merrill Lynch,Global Pharmaceutical, Biotech & Medtech 2007 Conference in ... BDT (11:00 am EDT) at the,Merrill Lynch Financial Centre. ... will be available to all,interested parties through the Investors ...
... a,biotechnology company translating the complexity of human biology ... president and,CEO, Dr. Keith O. Elliston, has been ... in Arlington, Va., September 17-18. Dr. Elliston ... Development and Commercial Value Added in Care Delivery ...
... ... and Reusable Bottles, MONROVIA, Calif., Sept. 12 Bottled or ... of consumers who fear the impact of,bottled water on the environment, ... assembled a family of products on its website, http://www.discovertesting.com, in ...
Cached Biology Technology:Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference 2Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference 3Genstruct CEO, Dr. Keith Elliston, Invited to Speak at Oncology Clinical Trial Summit 2Discover Testing Settles the Drinking Water Debate: Tap vs. Bottled 2
(Date:6/23/2015)... June 22, 2015 ... addition of the "Body-Worn Temperature Sensors Market ... and Forecast 2014 - 2020" report to ... analysis of the global body-worn temperature sensors market. ... segmented on the basis of types, care setting, ...
(Date:6/18/2015)... Conn. , June 18, 2015 NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market announces ... a featured segment on "Money on the Mark", scheduled to ... City June 20 th . ... will be from 7:00 to 8:00pm EST. NXT-ID, Inc.,s CEO ...
(Date:6/17/2015)... , June 17, 2015  Crossmatch™, a leading ... that its U.are.U ® 4500 fingerprint readers ... Eateries, Inc., a San Jose, ... to increase security, improve accountability and reduce fraud ... instant, non-repudiable identity confirmation for employee sign in ...
Breaking Biology News(10 mins):Body-Worn Temperature Sensors Market - Global Industry Analysis 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3
... today announced that it will launch EMBO Press on ... for The EMBO Journal , EMBO reports , ... provides opportunities for the future development of the journals. ... to encourage transparency in the publication process and help researchers make ...
... is derived from brain tumor stem cells, the source ... unclear. The potential of neural stem cells to transform ... but has not been confirmed. A team led by ... Nanjing Medical University, China found that doxycycline-induced neural stem ...
... Queen,s University Belfast is a lead partner in a ... new ways to treat Cystic Fibrosis. Affecting more ... is one of the most common life-threatening inherited diseases. ... death for patients., The new global programme, known as ...
Cached Biology News:EMBO announces the launch of EMBO Press 2Queen's University in €6m bid to find new Cystic Fibrosis treatments 2Queen's University in €6m bid to find new Cystic Fibrosis treatments 3
... consumable measurement plate for QPatch. ... controlled measurement sites. Each measurement ... flow channel system that enables ... and compound applications necessary for ...
This bispecific antibody complex has been tested for efficient depletion of CD41+ cells using the StemSep ; negative immunomagnetic cell separation system....
... to supply microplates, deepwells, and tips to ... in mind, iLink incorporates multiple functions into ... iLink software is the key to building ... can be copied and installed as turnkey ...
No-Weigh Dithiothreitol (DTT) ,7.7 mg DTT/Tube x 48 tubes...
Biology Products: